Maintenance of clinical remission in ANCA-associated vasculitis.
A fundamental change in management of antineutrophil cytoplasmic antibody-associated vasculitis in the past 10 years is the early focussed use of aggressive immunosuppression, using regimens comprised of widely available medications. Using a clinical framework to quantify morbidity, we can induce re...
| প্রধান লেখক: | |
|---|---|
| বিন্যাস: | Journal article |
| ভাষা: | English |
| প্রকাশিত: |
2013
|
| _version_ | 1826273295162408960 |
|---|---|
| author | Luqmani, R |
| author_facet | Luqmani, R |
| author_sort | Luqmani, R |
| collection | OXFORD |
| description | A fundamental change in management of antineutrophil cytoplasmic antibody-associated vasculitis in the past 10 years is the early focussed use of aggressive immunosuppression, using regimens comprised of widely available medications. Using a clinical framework to quantify morbidity, we can induce remission in most patients within 3-6 months using glucocorticoids plus methotrexate, cyclophosphamide or rituximab, with additional plasmapheresis when indicated. Difficulty in maintaining remission probably relates to the difference between true pathophysiological remission and the absence of clinical, serological or radiological evidence of disease activity. For surviving patients, the cumulative problems of relapse, burden of disease, or its treatment are coupled with pre-existing diseases or new conditions arising since diagnosis. Initial early control should reduce subsequent damage, but what effect it will have on relapse is not clear. In the absence of a cure, future trials should focus on reducing toxicity and comorbidity as well as controlling disease. |
| first_indexed | 2024-03-06T22:26:01Z |
| format | Journal article |
| id | oxford-uuid:56b05340-b11d-41f5-8680-618062de6cb5 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T22:26:01Z |
| publishDate | 2013 |
| record_format | dspace |
| spelling | oxford-uuid:56b05340-b11d-41f5-8680-618062de6cb52022-03-26T16:51:59ZMaintenance of clinical remission in ANCA-associated vasculitis.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:56b05340-b11d-41f5-8680-618062de6cb5EnglishSymplectic Elements at Oxford2013Luqmani, RA fundamental change in management of antineutrophil cytoplasmic antibody-associated vasculitis in the past 10 years is the early focussed use of aggressive immunosuppression, using regimens comprised of widely available medications. Using a clinical framework to quantify morbidity, we can induce remission in most patients within 3-6 months using glucocorticoids plus methotrexate, cyclophosphamide or rituximab, with additional plasmapheresis when indicated. Difficulty in maintaining remission probably relates to the difference between true pathophysiological remission and the absence of clinical, serological or radiological evidence of disease activity. For surviving patients, the cumulative problems of relapse, burden of disease, or its treatment are coupled with pre-existing diseases or new conditions arising since diagnosis. Initial early control should reduce subsequent damage, but what effect it will have on relapse is not clear. In the absence of a cure, future trials should focus on reducing toxicity and comorbidity as well as controlling disease. |
| spellingShingle | Luqmani, R Maintenance of clinical remission in ANCA-associated vasculitis. |
| title | Maintenance of clinical remission in ANCA-associated vasculitis. |
| title_full | Maintenance of clinical remission in ANCA-associated vasculitis. |
| title_fullStr | Maintenance of clinical remission in ANCA-associated vasculitis. |
| title_full_unstemmed | Maintenance of clinical remission in ANCA-associated vasculitis. |
| title_short | Maintenance of clinical remission in ANCA-associated vasculitis. |
| title_sort | maintenance of clinical remission in anca associated vasculitis |
| work_keys_str_mv | AT luqmanir maintenanceofclinicalremissioninancaassociatedvasculitis |